LABT (Lakewood-Amedex Biotherapeutics) Ending Cash Position: $0.01 Mil (As of Mar. 2026)


LABT Lakewood-Amedex Biotherapeutics Inc LABT
8 GF Score
Price $3.55
View Full Analysis

What is Lakewood-Amedex Biotherapeutics Ending Cash Position?

Lakewood-Amedex Biotherapeutics LABT +2.33% 8 Ending Cash Position is $0.01 Mil as of Mar. 2026. GuruFocus rates LABT with a GF Score™ of 8/100.

Lakewood-Amedex Biotherapeutics's Ending Cash Position for the quarter that ended in Mar. 2026 was $0.01 Mil.

Lakewood-Amedex Biotherapeutics's quarterly Ending Cash Position increased from Sep. 2025 ($0.00 Mil) to Dec. 2025 ($0.24 Mil) but then declined from Dec. 2025 ($0.24 Mil) to Mar. 2026 ($0.01 Mil).

Lakewood-Amedex Biotherapeutics's annual Ending Cash Position declined from Dec. 2023 ($2.53 Mil) to Dec. 2024 ($0.68 Mil) and declined from Dec. 2024 ($0.68 Mil) to Dec. 2025 ($0.24 Mil).

Lakewood-Amedex Biotherapeutics Ending Cash Position Related Terms

Lakewood-Amedex Biotherapeutics Ending Cash Position Historical Data

* Premium members only.

The historical data trend for Lakewood-Amedex Biotherapeutics's Ending Cash Position can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Lakewood-Amedex Biotherapeutics Ending Cash Position Chart

Lakewood-Amedex Biotherapeutics Annual Data
Trend Dec23 Dec24 Dec25
Ending Cash Position
2.53 0.68 0.24

Lakewood-Amedex Biotherapeutics Quarterly Data
Dec23 Sep24 Dec24 Mar25 Sep25 Dec25 Mar26
Ending Cash Position Get a 7-Day Free Trial 0.68 0.48 0.00 0.24 0.01
LABT
8GF Score
Lakewood-Amedex Biotherapeutics Inc LABT
Ending Cash Position is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Lakewood-Amedex Biotherapeutics Ending Cash Position Calculation

Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. It is equal to the Beginning Cash Position plus the Net Change in Cash.

Lakewood-Amedex Biotherapeutics's Ending Cash Position for the fiscal year that ended in Dec. 2025 is calculated as

Ending Cash Position= Beginning Cash Position+Net Change in Cash
=0.681+-0.445
=0.24

Lakewood-Amedex Biotherapeutics's Ending Cash Position for the quarter that ended in Mar. 2026 is calculated as

Ending Cash Position=Beginning Cash Position+Net Change in Cash
=0.237+-0.225
=0.01

Frequently Asked Questions Learn more about Ending Cash Position →
What does a Ending Cash Position of $0.01 Mil mean?
Lakewood-Amedex Biotherapeutics (LABT) has a Ending Cash Position of $0.01 Mil as of Mar. 2026. Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. View historical data on Lakewood-Amedex Biotherapeutics and its competitors.
Is Lakewood-Amedex Biotherapeutics' Ending Cash Position too high?
Lakewood-Amedex Biotherapeutics' current Ending Cash Position is $0.01 Mil. Overall, Lakewood-Amedex Biotherapeutics has a GF Score™ of 8/100, reflecting its overall financial health beyond just this single metric.
How does Lakewood-Amedex Biotherapeutics' Ending Cash Position compare to CURX and PBM?
Lakewood-Amedex Biotherapeutics' Ending Cash Position of $0.01 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Ending Cash Position for a Biotechnology company?
A good Ending Cash Position depends on the Biotechnology industry context. However, Ending Cash Position should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Ending Cash Position mean?
A high Ending Cash Position can signal that a stock is expensive relative to its fundamentals. Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. View historical data on Lakewood-Amedex Biotherapeutics and its competitors. Lakewood-Amedex Biotherapeutics's current Ending Cash Position is $0.01 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Lakewood-Amedex Biotherapeutics stock overvalued right now?
Lakewood-Amedex Biotherapeutics (LABT) has a current Ending Cash Position of $0.01 Mil. The current Ending Cash Position is $0.01 Mil. Lakewood-Amedex Biotherapeutics' overall GF Score™ is 8/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Ending Cash Position calculated?
Ending Cash Position is calculated from a company's financial statements. For Lakewood-Amedex Biotherapeutics (LABT), the current Ending Cash Position is $0.01 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Lakewood-Amedex Biotherapeutics Business Description

Address 8031 Cooper Creek Blvd, Unit 103, University Park, FL, USA, 34201
Lakewood-Amedex Biotherapeutics Inc is a clinical-stage biotechnology company developing a novel class of fast-acting, broad-spectrum antimicrobials - the Bisphosphocin class - to treat infectious diseases and reduce the threat posed by antibiotic-resistant bacterial strains, including MRSA, VRE, and others. The company's main product is Nu-3, a topically delivered antimicrobial gel in Phase 2 clinical trials for the treatment of mildly infected diabetic foot ulcers (iDFU). It is also advancing a portfolio of early-stage pipeline compounds developed from its Bisphosphocin platform targeting potential disease indications, including complicated urinary tract infection (cUTI) and pulmonary infections.
8GF Score

Get the complete analysis for LABT

Ending Cash Position is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$3.55
Price